Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679020 | 0.83 | HRH3 (0.67) | HRH3CYP1A2LTA4HCYP2D6CYP2C9 | |
| SCHEMBL1908631 | 0.83 | LTA4H (0.50) | CYP1A2LTA4HCYP2D6KDM4E | |
| SCHEMBL18837482 | 0.80 | HRH3 (0.58) | HRH3CYP1A2LTA4HCYP2D6CYP2C9 | |
| SCHEMBL678933 | 0.80 | KDM4E (0.55) | HRH3KDM4E | |
| SCHEMBL8795720 | 0.80 | KEAP1 (0.62) | HRH3CYP1A2LTA4HCYP2D6CYP2C9 | |
| SCHEMBL1283881 | 0.80 | KDM4E (0.58) | HRH3CYP1A2LTA4HCYP2D6CYP2C9 | |
| SCHEMBL20169587 | 0.80 | LMNA (0.53) | HRH3HTT | |
| SCHEMBL13652493 | 0.79 | LMNA (0.55) | CYP1A2LTA4HCYP2C19HTTKDM4E | |
| Hydrochloric Acid SCHEMBL10425852 | 0.78 | KDM4E (0.57) | HRH3KDM4E | |
| SCHEMBL4544705 | 0.78 | HRH3 (0.66) | HRH3LTA4HKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | ALK, BCR, NPM1 | HRH3 485/4885CYP1A2 1915/4885LTA4H 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.